31-Valent Pneumococcal Conjugate Vaccine Candidate Completes Phase 2 Enrollment

Anyone can get pneumococcal disease, but some people are at increased risk. To better protect children and seniors from disease, innovative vaccine candidates are conducting clinical trials in 2024.

Currently, two kinds of pneumococcal vaccines are recommended in the U.S. - Pneumococcal conjugate vaccines (PCVs, specifically PCV15 and PCV20) and Pneumococcal polysaccharide vaccine (PPSV23).

However, even with U.S. FDA-approved vaccines broadly available, approximately 5,000 deaths are related to pneumococcal disease each year in the U.S.

To address this health issue, Vaxcyte, Inc. today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a next-generation 31-valent PCV and the broadest-spectrum pneumococcal vaccine candidate in the clinic today. 

This vaccine candidate is designed to prevent invasive pneumococcal disease (IPD).

Vaxcyte expects to announce topline safety, tolerability, and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.

"Completing the enrollment of the VAX-31 study with more than one thousand adults 50 years and older is a significant step for our PCV franchise, and we look forward to announcing topline safety, tolerability, and immunogenicity data in the third quarter of this year," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte, in a press release.

"VAX-31, the broadest-spectrum PCV in the clinic, has the potential to address a significant public health need by covering approximately 95% of IPD circulating in the U.S. adult population while maintaining coverage of previously circulating strains that are currently contained via ongoing vaccination."

Vaxcyte's unedited press release is posted here.